Baidu Announces Project Apollo, Opening Up its Autonomous Driving Platform
Baidu Announces Project Apollo, Opening Up its Autonomous Driving Platform April 18, 2017 21:15 ET | Source: Baidu BEIJING, CHINA--(Marketwired - Apr 18, 2017) - Baidu, Inc. (NASDAQ: BIDU), Baidu has today announced a new project named "Apollo" which will provide an open, complete and reliable software platform for its partners in the automotive and autonomous driving industry to develop their own
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN
Global Cloud Index Projects Cloud Traffic to Represent 95 Percent of Total Data Center Traffic by 2021
NEW REPORT: Legal Marijuana Industry to Generate $40 billion in Economic Impact by 2021
ABB and HPE Bring Intelligence to Industrial Plants
Calyx Commences Crypto Mining and Blockchain Validation Operations at Second Data Centre
Enter Fortifies Carrier-Neutral Interconnection Capabilities at Its Caldera Park Data Center in Milan
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma
Plazomicin Granted FDA Breakthrough Therapy Designation
YARA and KONGSBERG enter into partnership to build world's first autonomous and zero emissions ship
MHI Vestas Offshore Wind has received a 406 MW order in Denmark
Firsthand Technology Value Fund Discloses Top Portfolio Holdings
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES
Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease
Zealand announces that Sanofi has submitted LixiLan for regulatory review in the US, triggering a USD 20 million milestone payment
Biota Announces Positive Phase 1 Data for Direct-Acting RSV Antiviral BTA585 
Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA